Clinical Trials
68 trialsOctreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
ACTION-1
RayzeBio, Inc.
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
NETTER-2
Advanced Accelerator Applications
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
PANENCA
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OXTEND-01
Debiopharm International SA
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
PANasta
University of Liverpool
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
OTIS
Karolinska University Hospital
SAUNA
University Hospital, Antwerp
The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
St. James's Hospital, Ireland
Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
St. James's Hospital, Ireland
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Changhai Hospital
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
Clinica Universidad de Navarra, Universidad de Navarra
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Eastern Cooperative Oncology Group
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
Eastern Cooperative Oncology Group
CEVOREM
Assistance Publique Hopitaux De Marseille
The Effect of Octreotide on Wound Drainage After Mastectomy
University College Hospital, Ibadan
Palliative Management of Inoperable Malignant Bowel Obstruction
Roswell Park Cancer Institute
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
SANDOSTATINE
Institut Cancerologie de l'Ouest
NETTER-1
Advanced Accelerator Applications
EndoGut
St. James's Hospital, Ireland
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
CSMS99
National Cancer Institute, Naples
Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
AdventHealth
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Canadian Cancer Trials Group
Stress, Diurnal Cortisol, and Breast Cancer Survival
Stanford University
SCIROCCO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Massachusetts General Hospital
Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs
Peking Union Medical College Hospital
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
University of Regensburg
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Alliance for Clinical Trials in Oncology
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
Novartis
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Novartis
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Novartis
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion
Saint Vincent's Hospital, Korea
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Alliance for Clinical Trials in Oncology
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Novartis
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
SCRI Development Innovations, LLC